Archemix Corporation

Iveric Bio, Inc.

Charles Wilson

David Epstein

Thomas Greene McCauley

Markus Kurz

James Rottman

Claude Benedict

Jeffrey C Kurz

John Louis Diener

Dilara McCauley

Dilara Grate

Thomas Green Mccauley

Martin Stanton

Sara Chesworth Keene

Anna J Zoltoski

Paul Hatala

Thomas Mccauley

Kristin Thompson

Jess Wagner-Whyte

Dilârâ McCauley

Jeffrey Kurz

Kristin A Marshall

Tony Keefe

Nobuko Hamaguchi

Errol Desouza

John Deiner

Jeffrey Preiss

The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.

Aptamer therapeutics useful in the treatment of complement-related disorders

Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto.

Aptamers comprising CPG motifs

Methods are provided for identifying aptamer regulators. Aptamer regulators are aptamers that bind to a target wherein binding of the aptamer regulator to the target increases the binding affinity of the target for a target partner relative to the affinity of the target for the target partner when the target is not bound by the aptamer regulator such that binding of the aptamer regulator to the target is a prerequisite for target-target partner complex formation.

Methods for identifying aptamer regulators

Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics

Materials and methods of use thereof are presented for the treatment of diabetes and other diseases. Therapeutic compositions including regulated aptamer therapeutic compositions with specificity to components of diabetes disease are presented with methods of administering these therapeutic compositions.

Regulated aptamer therapeutics

The present invention provides stabilized, high affinity nucleic acid ligands to PSMA. Methods for the identification and preparation of novel, stable, high affinity ligands to PSMA using the SELEX&#x2122; method with 2'-O-methyl substituted nucleic acids, and cell surface SELEX&#x2122; are described herein. Also included are methods and compositions for the treatment and diagnosis of disease characterized by PSMA expression, using the described nucleic acid ligands.

Stabilized aptamers to PSMA and their use as prostate cancer therapeutics

Growing community of inventors

Concord, MA, United States of America

Charles Wilson